| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.21.5.424.34497 |
| P698 | PubMed publication ID | 11310515 |
| P2093 | author name string | C Gillotin | |
| C Katlama | |||
| F Raffi | |||
| G J Yuen | |||
| A C Crémieux | |||
| AZl10002 Study Group | |||
| D Demarles | |||
| P2860 | cites work | Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. | Q51563075 |
| How Many Pills Do Patients With HIV Infection Take? | Q57955548 | ||
| Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection | Q58292059 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | zidovudine | Q198504 |
| abacavir | Q304330 | ||
| pharmacokinetics | Q323936 | ||
| lamivudine | Q422631 | ||
| P304 | page(s) | 424-430 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults | |
| P478 | volume | 21 |
| Q34778565 | A review of the pharmacokinetics of abacavir |
| Q36739802 | Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection |
| Q46233887 | Adherence to combined Lamivudine + Zidovudine versus individual components: a community-based retrospective medicaid claims analysis |
| Q33914723 | Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? |
| Q42067473 | Effect of the HIV nucleoside reverse transcriptase inhibitor zidovudine on the growth and differentiation of primary gingival epithelium |
| Q41999400 | HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium |
| Q35583718 | Hepatitis B reactivation and rituximab in the oncology practice. |
| Q39961994 | Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy |
| Q35013781 | Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects |
| Q35128642 | Lamivudine/zidovudine/abacavir: triple combination tablet |
| Q34635561 | Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour? |
| Q37346797 | Nucleoside reverse transcriptase inhibitors induce a mitophagy-associated endothelial cytotoxicity that is reversed by coenzyme Q10 cotreatment. |
| Q35947409 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children |
| Q38868724 | Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. |
| Q37708677 | Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children |
| Q37263890 | Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children |
| Q37404670 | Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assay |
| Q35808707 | Spillover adherence effects of fixed-dose combination HIV therapy |
| Q34111703 | Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis |
| Q38216047 | The role of formulation on the pharmacokinetics of antiretroviral drugs. |
| Q34628638 | Trizivir |
| Q44657176 | Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial |
Search more.